RT Journal Article
SR Electronic
T1 β-Catenin Expression Correlates With Prognosis in Hepatocellular Carcinoma Patients Treated With Transcatheter Arterial Chemoembolization
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1129
OP 1134
DO 10.21873/anticanres.13221
VO 39
IS 3
A1 XIANGXIAN XU
A1 DAZHI GAO
A1 XIAOLI YUAN
A1 LI LIU
A1 XIANG ZHANG
A1 XIANXIAN LIANG
A1 SUI CHEN
A1 MIN AI
A1 BO CHEN
A1 DONGHONG SHI
A1 ZHIJIAN YANG
A1 ROBERT M. HOFFMAN
A1 JIAN XU
YR 2019
UL http://ar.iiarjournals.org/content/39/3/1129.abstract
AB Background/Aim: Transcatheter arterial chemoembolization (TACE) is one of the most widely used palliative therapies for the unresectable hepatocellular carcinoma (HCC). However, a large difference is found in prognosis among patients treated with TACE. The aim of the present study was to investigate the prognostic value of β-catenin in HCC patients treated with TACE. Materials and Methods: Seventy patients with HCC were included in this study. Expression of β-catenin was determined by immunohistochemistry in biopsy samples taken before TACE. The patients were treated with TACE and followed-up. Clinicopathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated to analyze the association of β-catenin expression with prognosis for HCC patients after TACE. Results: HCC patient biopsies exhibited a significantly higher positive rate of β-catenin expression (72.86%) compared to paracancer normal tissues (19.44%) (p<0.01). β-Catenin expression was closely correlated with tumor differentiation, tumor size, serum α-fetoprotein (AFP) level and TACE treatment frequency (all p<0.05). Patients with negative β-catenin expression had longer PFS and OS after TACE compared to those with positive β-catenin expression (PFS: 44.2 vs. 14.1 months, p=0.004; OS: 56.4 vs. 35.9 months, p<0.001). Multivariate Cox regression analysis indicated that β-catenin expression in HCC patients treated with TACE was an independent prognostic factor for higher PFS and OS. Conclusion: The HCC patients with increased β-catenin expression have a poor prognosis with lower survival rate.